Editorial: GLP-1 receptor agonists in inflammatory bowel disease-Is it time?

Konstantinos Arvanitakis^{1

2}, Georgios Germanidis^{1

2}

Affiliations

¹ Division of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Editorial

Konstantinos Arvanitakis et al. Aliment Pharmacol Ther. 2024 Sep.

. 2024 Sep;60(5):658-659.

doi: 10.1111/apt.18152. Epub 2024 Jul 21.

Konstantinos Arvanitakis^{1

2}, Georgios Germanidis^{1

2}

¹ Division of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

No abstract available

References

1. Arvanitakis K, Koufakis T, Popovic D, Maltese G, Mustafa O, Doumas M, et al. GLP‐1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use. Curr Obes Rep. 2023;12(2):61–74. https://doi.org/10.1007/s13679‐023‐00506‐3
1. Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019. BMJ Open. 2023;13(3):e065186. https://doi.org/10.1136/bmjopen‐2022‐065186
1. Desai A, Petrov J, Hashash JG, Patel H, Brahmbhatt B, Kochhar GS, et al. Use of glucagon‐like Peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;60:620–632.
1. Biagioli M, Marchianò S, Roselli R, Di Giorgio C, Bellini R, Bordoni M, et al. GLP‐1 mediates regulation of colonic ACE2 expression by the bile acid receptor GPBAR1 in inflammation. Cells. 2022;11(7):1187.
1. Villumsen M, Schelde AB, Jimenez‐Solem E, Jess T, Allin KH. GLP‐1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine. 2021;37:100979. https://doi.org/10.1016/j.eclinm.2021.100979